Antonio Antela

3.9k total citations
49 papers, 947 citations indexed

About

Antonio Antela is a scholar working on Infectious Diseases, Emergency Medicine and Virology. According to data from OpenAlex, Antonio Antela has authored 49 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Infectious Diseases, 19 papers in Emergency Medicine and 18 papers in Virology. Recurrent topics in Antonio Antela's work include HIV/AIDS Research and Interventions (31 papers), HIV/AIDS drug development and treatment (22 papers) and HIV-related health complications and treatments (19 papers). Antonio Antela is often cited by papers focused on HIV/AIDS Research and Interventions (31 papers), HIV/AIDS drug development and treatment (22 papers) and HIV-related health complications and treatments (19 papers). Antonio Antela collaborates with scholars based in Spain, United States and United Kingdom. Antonio Antela's co-authors include Santiago Moreno, Fernando Dronda, Maria Jesús Pérez‐Elías, José L. Casado, Ana Moreno, Carmen Quereda, Félix Gutiérrez, Juan Berenguer, Peré Domingo and Rafael Rubio and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Antonio Antela

47 papers receiving 915 citations

Peers

Antonio Antela
Paola Cicconi Italy
Paola Meraviglia Italy
Wisit Prasithsirikul Thailand
Jean van Wyk United Kingdom
George Perez United States
Marek Beniowski Poland
Jennifer S Fusco United States
Daniel Seekins United States
Carlos Malvestutto United States
Barbara Gripshover United States
Paola Cicconi Italy
Antonio Antela
Citations per year, relative to Antonio Antela Antonio Antela (= 1×) peers Paola Cicconi

Countries citing papers authored by Antonio Antela

Since Specialization
Citations

This map shows the geographic impact of Antonio Antela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Antela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Antela more than expected).

Fields of papers citing papers by Antonio Antela

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Antela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Antela. The network helps show where Antonio Antela may publish in the future.

Co-authorship network of co-authors of Antonio Antela

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Antela. A scholar is included among the top collaborators of Antonio Antela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Antela. Antonio Antela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brañas, Fátima, Miguel Torralba, Antonio Antela, et al.. (2023). Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV. BMC Geriatrics. 23(1). 4–4. 19 indexed citations
2.
Moreno, Santiago, Bernardino Alcázar Navarrete, Carlos Dueñas, et al.. (2022). Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir. SHILAP Revista de lepidopterología. 15 indexed citations
3.
Antela, Antonio, José Ignacio Bernardino, P Bachiller, et al.. (2022). Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges. Infectious Diseases and Therapy. 11(5). 2017–2033. 1 indexed citations
4.
Mantsios, Andrea, Miranda Murray, Tahilin Sanchez Karver, et al.. (2021). Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Services Research. 21(1). 255–255. 34 indexed citations
5.
Araújo‐Vilar, David, Antía Fernández‐Pombo, Gemma Rodríguez-Carnero, et al.. (2020). LipoDDx: a mobile application for identification of rare lipodystrophy syndromes. Orphanet Journal of Rare Diseases. 15(1). 81–81. 5 indexed citations
6.
Domingo, Peré, Ignacio Suárez-Lozano, Félix Gutiérrez, et al.. (2019). Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrología. 39(5). 497–505. 6 indexed citations
7.
Estrada, Vicente, Peré Domingo, Ignacio Suárez-Lozano, et al.. (2019). Riesgo de enfermedad cardiovascular en pacientes con infección VIH en tratamiento antirretroviral. Revista Clínica Española. 220(3). 149–154. 1 indexed citations
8.
Antela, Antonio, et al.. (2018). Prevención primaria. Enfermedades Infecciosas y Microbiología Clínica. 36. 31–34.
9.
Gazzard, Brian, Shehzad Ali, Axel Mühlbacher, et al.. (2014). Patient preferences for characteristics of antiretroviral therapies: results from five European countries. Journal of the International AIDS Society. 17(4S3). 19540–19540. 14 indexed citations
10.
Hernando, Víctoria, Paz Sobrino‐Vegas, Juan Berenguer, et al.. (2012). Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS. 26(14). 1829–1834. 24 indexed citations
11.
Martínez, Estebán, Josep M. Llibre, Félix Gutiérrez, et al.. (2012). Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 26(18). 2315–2326. 106 indexed citations
12.
Pérez‐Molina, José A., Ignacio Suárez-Lozano, Alfonso del Arco, et al.. (2011). Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status. HIV Clinical Trials. 12(1). 1–8. 11 indexed citations
13.
Antela, Antonio, et al.. (2008). Formación especializada de posgrado en patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica. 26. 51–64. 2 indexed citations
14.
Hernández‐Novoa, Beatriz, Antonio Antela, Carolina Gutiérrez, et al.. (2008). Effect of food on the antiviral activity of didanosine enteric‐coated capsules: a pilot comparative study*. HIV Medicine. 9(4). 187–191. 7 indexed citations
15.
Moreno, Ana, Alberto Moreno, Maria Jesús Pérez‐Elías, et al.. (2006). Syncytial giant cell hepatitis in human immunodeficiency virus–infected patients with chronic hepatitis C: 2 cases and review of the literature. Human Pathology. 37(10). 1344–1349. 16 indexed citations
16.
Hernández, Beatríz, Santiago Moreno, Maria Jesús Pérez‐Elías, et al.. (2006). Severity of the Toxicity Associated With Combinations That Include Didanosine Plus Stavudine in HIV-Infected Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 556–559. 3 indexed citations
17.
18.
Pérez‐Elías, Maria Jesús, Ana Moreno, Santiago Moreno, et al.. (2003). Differences in Durability of Treatment with Initial PI-Based Regimens. HIV Clinical Trials. 4(6). 391–399. 5 indexed citations
19.
Dronda, Fernando, Santiago Moreno, Maria Jesús Pérez‐Elías, et al.. (2002). Vascular disease in HIV-infected patients. AIDS. 16(14). 1971–1973. 8 indexed citations
20.
Dronda, Fernando, José L. Casado, Santiago Moreno, et al.. (2001). Phenotypic Cross-Resistance to Nelfinavir: The Role of Prior Antiretroviral Therapy and the Number of Mutations in the Protease Gene. AIDS Research and Human Retroviruses. 17(3). 211–215. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Cicconi Breakdown of academic impact, for papers by Paola Meraviglia Breakdown of academic impact, for papers by Wisit Prasithsirikul Breakdown of academic impact, for papers by Jean van Wyk Breakdown of academic impact, for papers by George Perez Breakdown of academic impact, for papers by Marek Beniowski Breakdown of academic impact, for papers by Jennifer S Fusco Breakdown of academic impact, for papers by Daniel Seekins Breakdown of academic impact, for papers by Carlos Malvestutto Breakdown of academic impact, for papers by Barbara Gripshover
Rankless by CCL
2026